Cost-effectiveness analysis of adult pneumococcal conjugate vaccines for pneumococcal disease in Japan

Cost-effectiveness analysis of adult pneumococcal conjugate vaccines for pneumococcal disease in Japan

Background The 23-valent pneumococcal polysaccharide vaccine (PPSV23) is used in the Japanese National Immunization Program for older adults and adults with increased risk for pneumococcal disease, however, disease incidence and associated burden remain high. We evaluated the cost-effectiveness of p...

Full description

Saved in:
Bibliographic Details
Main Authors: Shigeki Nakamura, Masashi Mikami, Tomoyuki Hayamizu, Naohiro Yonemoto, Camille Moyon, Mark Gouldson, Catriona Crossan, Jeffrey Vietri, Kazumasa Kamei
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Expert Review of Vaccines
Subjects:
Cost-effectiveness
invasive pneumococcal disease
Japan
PCV20
pneumococcal disease
vaccination
Online Access:https://www.tandfonline.com/doi/10.1080/14760584.2024.2350246
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/14760584.2024.2350246

Similar Items